World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

Pharmaceutical Technology

MAY 28, 2024

Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant advantages

RNA 163

RNA Vaccine Vaccination 163

Bio Pharma Dive

AUGUST 16, 2022

The pharmaceutical company has formed an alliance with Orna and invested $100 million in its Series B round, hoping the young biotech’s approach could lead to multiple new vaccines and drugs.

RNA 293

RNA Vaccine Vaccination Drugs 293

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

Vaccine 291

Vaccine Vaccination Gene Therapy RNA 291

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 16, 2022

The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.

Vaccine 242

Vaccine Vaccination RNA Development 242

Bio Pharma Dive

MARCH 18, 2021

A treatment that sprays synthetic messenger RNA into the lungs failed to help cystic fibrosis patients, a blow to efforts to use the technology for more than vaccines.

RNA 322

RNA Vaccine Vaccination Drugs 322

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccine 245

Vaccine Vaccination Development RNA 245

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Vaccine 290

Vaccine Vaccination Development Immune Response 290

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 148

RNA Vaccine Vaccination In-Vivo 148

Bio Pharma Dive

AUGUST 22, 2024

The approval of both reformulated messenger RNA vaccines, which are designed to target the KP.2 2 virus strain, comes just ahead of the fall and winter seasons.

RNA 282

RNA Vaccine Vaccination 282

Bio Pharma Dive

MAY 19, 2023

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 300

RNA Medicine Clinical Trials Clinical Trials 300

Pharmaceutical Technology

MARCH 1, 2023

The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.

RNA 148

RNA Vaccine Vaccination Genetics 148

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineer 263

Engineer Vaccine Vaccination Clinical Trials 263

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccine 53

Vaccine Vaccination RNA Development 53

Pharmaceutical Technology

JULY 15, 2022

Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada.

Vaccine 265

Vaccine Vaccination Gene Therapy Antibody 265

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccine 294

Vaccine Vaccination Antibody Trials 294

Pharmaceutical Technology

MAY 23, 2023

ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”

RNA 148

RNA Gene Editing Gene Vaccine 148

Pharmaceutical Technology

MAY 15, 2024

CircRNA is still in early days of development, but could be in trials as vaccines, therapeutics and biomarkers in the next few years.

RNA 148

RNA Vaccine Vaccination Trials 148

Pharmaceutical Technology

APRIL 16, 2024

Sanofi has signed an agreement with IDT Australia for preclinical formulation development of its messenger RNA (mRNA) vaccines.

Vaccine 148

Vaccine Vaccination Development RNA 148

Pharmaceutical Technology

APRIL 27, 2023

Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.

RNA 130

RNA Medicine Gene Therapy Gene 130

Pharmaceutical Technology

NOVEMBER 2, 2023

While things may have slowed down a little since the rapid approvals of the COVID-19 vaccines, the excitement around RNA-LNP is still going strong.

RNA 130

RNA Manufacturing Vaccine Vaccination 130

pharmaphorum

MAY 2, 2024

A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.

RNA 115

RNA Vaccine Vaccination Trials 115

pharmaphorum

NOVEMBER 29, 2023

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.

RNA 115

RNA Regulation Vaccine Vaccination 115

Bio Pharma Dive

OCTOBER 6, 2022

A new agreement with the Australian government will bring messenger RNA research and manufacturing capabilities to the country, adding to the COVID-19 vaccine developer’s global expansion efforts.

RNA 205

RNA Manufacturing Vaccine Vaccination 205

BioSpace

AUGUST 4, 2021

RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins.

RNA 96

RNA Protein Vaccine Vaccination 96

Pharmaceutical Technology

DECEMBER 19, 2023

BioNTech has inaugurated a new messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda, which will have BioNTainers.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

Pharmaceutical Technology

JUNE 30, 2022

HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.

Vaccine 163

Vaccine Vaccination Clinical Trials Clinical Trials 163

pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 billion, consummating a relationship that first started in 2018 and spanned a range of mRNA-based vaccines for infectious diseases. billion, including $150 million upfront.

RNA 98

RNA Vaccine Vaccination Clinical Trials 98

BioSpace

APRIL 11, 2021

Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.

Vaccine 142

Vaccine Vaccination RNA Development 142

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

Bio Pharma Dive

AUGUST 22, 2022

The decision will make a third vaccine available for children 12 to 17 years old in the U.S., giving them an option that doesn’t use the messenger RNA technology of shots by Pfizer and Moderna.

Vaccine 130

Vaccine Vaccination RNA 130

STAT News

NOVEMBER 24, 2022

An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine.

Vaccine 138

Vaccine Vaccination Immune Response Development 138

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccine Vaccination Sales 98

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Pharmaceutical Technology

SEPTEMBER 1, 2022

The US Food and Drug Administration (FDA) has granted Emergency Use Authorizations (EUAs) for bivalent formulations of Moderna and Pfizer -BioNTech’s Covid-19 vaccines as boosters. According to the amended EUA, the vaccines are indicated to be administered at a minimum of two months after the initial or booster dose.

Vaccine 261

Vaccine Vaccination Gene Therapy RNA 261

pharmaphorum

MARCH 16, 2021

European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. As it conducted its analysis of the vaccine in December, the European Medicines Agency’s systems were targeted by unknown hackers.

Regulation 138

Regulation Vaccine Vaccination RNA 138

Bio Pharma Dive

SEPTEMBER 17, 2020

The Novartis plant will help BioNTech and partner Pfizer make 750 million doses of their shot per year, and become one of the largest messenger RNA manufacturing sites in Europe.

Manufacturing 162

Manufacturing RNA Vaccine Vaccination 162